Amylyx Pharmaceuticals, Inc.
AMLX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $87,371 | $380,786 | $22,230 | $0 |
| % Growth | -77.1% | 1,612.9% | – | – |
| Cost of Goods Sold | $42,156 | $25,441 | $2,993 | $0 |
| Gross Profit | $45,215 | $355,345 | $19,237 | $0 |
| % Margin | 51.8% | 93.3% | 86.5% | – |
| R&D Expenses | $104,084 | $128,187 | $93,450 | $44,040 |
| G&A Expenses | $111,631 | $178,856 | $122,728 | $38,933 |
| SG&A Expenses | $114,331 | $188,356 | $127,128 | $38,933 |
| Sales & Mktg Exp. | $2,700 | $9,500 | $4,400 | $0 |
| Other Operating Expenses | $141,531 | $0 | $0 | -$285 |
| Operating Expenses | $359,946 | $316,543 | $220,578 | $82,688 |
| Operating Income | -$314,731 | $38,802 | -$201,341 | -$82,688 |
| % Margin | -360.2% | 10.2% | -905.7% | – |
| Other Income/Exp. Net | $12,595 | $15,495 | $3,740 | -$5,243 |
| Pre-Tax Income | -$302,136 | $54,297 | -$197,601 | -$87,931 |
| Tax Expense | -$393 | $5,026 | $774 | $0 |
| Net Income | -$301,743 | $49,271 | -$198,375 | -$87,931 |
| % Margin | -345.4% | 12.9% | -892.4% | – |
| EPS | -4.43 | 0.73 | -2.98 | -1.52 |
| % Growth | -706.8% | 124.5% | -96.1% | – |
| EPS Diluted | -4.43 | 0.7 | -2.98 | -1.52 |
| Weighted Avg Shares Out | 68,142 | 67,234 | 66,512 | 57,864 |
| Weighted Avg Shares Out Dil | 68,142 | 69,991 | 66,512 | 57,864 |
| Supplemental Information | – | – | – | – |
| Interest Income | $13,809 | $16,155 | $4,291 | $36 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $904 | $1,088 | $487 | $52 |
| EBITDA | -$290,976 | $39,890 | -$200,854 | -$82,636 |
| % Margin | -333% | 10.5% | -903.5% | – |